placeholder
Importance
55
Trust
70
Urgency
30
REGULATORY · PRIMARY SOURCE
Momentum Health 360 dba Momentum Health - 728286 - 06/08/2026
The FDA fined Momentum Health 360 for making false claims on its website about compounded weight-loss drugs like semaglutide and tirzepatide. The company falsely said its compounded drugs were FDA-approved and that it was a licensed compounder, when compounded drugs are not FDA-approved and pharmacies don't get FDA licenses.
Analysis
FDA keeps cracking down on compounders making false claims. Companies selling compounded semaglutide and tirzepatide face seizure or injunction if they don't fix their websites fast.
- FDA issued warning letter MARCS-CMS 728286 to Momentum Health 360 on June 8, 2026
- Website falsely claimed compounded semaglutide and tirzepatide were from an 'FDA-licensed' facility
- Violations found during FDA website review conducted in March 2026; company has 15 business days to respond
FDA Drug Approvals & Databases4d
Read